Angiotensin II (Ang II) is a peptide hormone that, like many cytokines, acts as a proinflammatory agent and growth factor. After injury to the liver, the hormone assists in tissue repair by stimulating hepatocytes and hepatic stellate cells to synthesize extracellular matrix proteins and secrete secondary cytokines and by stimulating myofibroblasts to proliferate. However, under conditions of chronic liver injury, all of these effects conspire to promote pathologic liver fibrosis. Much of this effect of Ang II results from activation of the proinflammatory NF-B transcription factor in response to stimulation of the type 1 Ang II receptor, a G protein-coupled receptor. Here, we characterize a previously undescribed signaling pathway mediating Ang II-dependent activation of NF-B, which is composed of three principal proteins, CARMA3, Bcl10, and MALT1. Blocking the function of any of these proteins, through the use of either dominant-negative mutants, RNAi, or gene targeting, effectively abolishes Ang II-dependent NF-B activation in hepatocytes. In addition, Bcl10 ؊/؊ mice show defective hepatic cytokine production after Ang II treatment. Evidence also is presented that this pathway activates NF-B through ubiquitination of IKK␥, the regulatory subunit of the IB kinase complex. These results elucidate a concrete series of molecular events that link ligand activation of the type 1 Ang II receptor to stimulation of the NF-B transcription factor. These findings also uncover a function of the CARMA, Bcl10, and MALT1 proteins in cells outside the immune system. G protein-coupled receptor ͉ hepatocyte ͉ IkB kinase ͉ inflammation ͉ ubiquitination
G protein-coupled receptor ͉ hepatocyte ͉ IkB kinase ͉ inflammation ͉ ubiquitination A lthough classically known for its role in acute blood pressure regulation, angiotensin II (Ang II) now is recognized to act as a powerful proinflammatory mediator in numerous tissues, including the heart, arteries, liver, and kidney (1) . The liver is an example of a major target organ of Ang II proinflammatory action, because both hepatocytes and hepatic stellate cells express the type I Ang II receptor (AT 1 R), a member of the seven transmembranespanning G protein-coupled receptor superfamily (2) (3) (4) . In several experimental models of liver injury, AT 1 -dependent Ang II signaling has been shown to be crucial for the development of hepatic fibrosis and cirrhosis, effects that are related to its induction of acute phase reactants, inflammatory and fibrogenic cytokines, and extracellular matrix proteins (5) (6) (7) (8) (9) (10) (11) . These effects of Ang II appear independent of the underlying source of injury and have been documented in settings as diverse as bile-duct stenosis and CCl 4 poisoning (7, 8) . Consequently, it is thought that Ang II is an amplifier of the general inflammatory response to chronic liver injury but plays a particularly critical role because all components of the local renin-angiotensin system are dramatically up-regulated in the setting of liver injury, leading to excess local production of Ang II (12, 13) .
Ligand activation of the AT 1 R, which mediates most of the known effects of Ang II in liver, leads to rapid stimulation of PKC isoforms (14) . Subsequently, it is the PKC-dependent activation of NF-B that appears crucial for many of the proinflammatory effects of Ang II (1) . NF-B is a family of transcription factors that function as dimers, with the prototypic example being a heterodimer of relA (p65) and p50 (15) . In resting cells, NF-B dimers are sequestered in an inactive state in the cytoplasm through interaction with inhibitory IB proteins. Upon cell activation, most pathways of NF-B induction have been shown to converge at the level of the IB kinase (IKK), a kinase complex that, when stimulated, phosphorylates IB and, thereby, marks it for proteosomal degradation (15) . This event results in the release of NF-B, which then is free to translocate to the nucleus and enhance expression of various proinflammatory genes. Despite the importance of this NF-B signaling pathway in mediating proinflammatory effects of Ang II in both liver and other tissues, the molecular events that link AT 1 R-dependent activation of PKC with subsequent stimulation of NF-B remain unknown.
We and others recently have described a similar signaling pathway that mediates antigen-induced lymphocyte proliferation by bridging T or B cell receptor-dependent activation of PKC with the stimulation of NF-B (16). The pathway includes three major signaling molecules: (i) CARMA1 [caspase recruitment domain (CARD) 11͞Bimp3], a member of the membraneassociated guanylate-kinase superfamily of scaffolding proteins, which serves to integrate the upstream signal of activated PKC with downstream factors (17) (18) (19) (20) ; (ii) Bcl10, an intermediate bridging factor (21) (22) (23) (24) ; and (iii) MALT1, an effector protein that, when oligomerized through interaction with Bcl10, either directly or indirectly stimulates the IKK complex (25) (26) (27) (28) . This pathway is exclusive to the immune system because of the highly restricted expression pattern of CARMA1, which is found chiefly in lymphocytes (17, 18) . However, a second member of the CARMA family, CARMA3 (CARD10͞Bimp1), appears to have a wider tissue distribution profile (19, 29) . Thus, because of the parallels between antigen-and Ang II-dependent NF-B activation, we wondered whether CARMA3 might coordinate an analogous signaling pathway in Ang II-responsive tissues such as the liver.
In this article, we demonstrate that CARMA3, Bcl10, and MALT1 form the backbone of a previously undescribed signal-ing pathway for Ang II in liver. We also present evidence to suggest that ubiquitination of IKK␥, an effect that is mediated by MALT1 in the parallel, lymphocyte pathway, is a critical event in Ang II-dependent NF-B activation. The results uncover a physiologic role for CARMA3 and indicate that Bcl10 and MALT1 have a major role in NF-B signaling outside of the immune system.
Results

CARMA3, Bcl10, and MALT1 Are Expressed in Ang II-Responsive
Tissues, Unlike CARMA1. To address whether CARMA3 might coordinate the AT 1 -dependent activation of NF-B, we first performed real-time quantitative RT-PCR to compare the relative abundance of CARMA3 mRNA in various mouse tissues with that of the AT 1 R. As expected, the AT 1 R mRNA was highest in heart, followed closely by liver and kidney, all tissues known to be responsive to Ang II (Fig. 1A) . CARMA3 mRNA showed a relatively similar pattern of expression (Fig. 1B) . In contrast, CARMA1 mRNA was present almost exclusively in spleen and thymus (Fig. 1C) , consistent with previous reports indicating that CARMA1 expression is largely restricted to lymphocytes (17, 18) .
Although a role for Bcl10 and MALT1 in cell signaling thus far has been described only in cells of the immune system, we found that both Bcl10 and MALT1 mRNAs were expressed somewhat homogeneously across a wide variety of epithelial and mesenchymal tissues ( Fig. 1 D and E) . In general, Bcl10 and MALT1 were expressed at least as abundantly in the Ang II-responsive tissues of heart, liver, and kidney as they were in spleen or thymus. Western blotting confirmed that these findings also hold at the protein level, by demonstrating the presence of Bcl10 and MALT1 protein in liver at levels comparable to those seen in spleen and thymus (Fig. 1F) . Consistent with the RT-PCR results, Western blotting also detected CARMA3 protein in liver but not in the spleen or thymus (Fig. 1F ).
CARMA3 Is an Essential Mediator of Ang II-Dependent NF-B Signal-
ing. Because all components of a putative CARMA3͞Bcl10͞ MALT1 signaling pathway are present within liver, a major target for Ang II action, we speculated that such a pathway might mediate the Ang II-dependent activation of NF-B in hepatocytes. To test our hypothesis, we used an Ang II-responsive HepG2 hepatocyte cell model established by Brasier and colleagues (30, 31) . First, we confirmed that Ang II-dependent NF-B activation in these cells occurs through the canonical pathway. Specifically, we showed that Ang II treatment results in stimulation of the IKK complex within minutes, as well as phosphorylation and degradation of IB␣ ( Fig. 6 A and B, which is published as supporting information on the PNAS web site). Next, we addressed the role of CARMA3 by analyzing the effect of a dominant-negative mutant of CARMA3 on Ang IIdependent NF-B activation. This mutant, CARMA3⌬CARD ( Fig. 2A) , has a selective deletion of the CARD, a protein interaction domain known to mediate the recruitment of the downstream signaling protein, Bcl10, through a homotypic CARD-CARD interaction (19) . An analogous mutant of CARMA1 blocks antigen-dependent NF-B activation in the lymphocyte, presumably by interrupting transmission of the signal from activated PKC to the downstream effectors, Bcl10 and MALT1 (19, 20, 32, 33) . Thus, we anticipated that the CARMA3⌬CARD mutant would block NF-B activation if a CARMA3͞Bcl10͞MALT1 pathway indeed is required for Ang II signaling. Under control conditions, we found that both Ang II and TNF␣-induced NF-B to a similar degree, but when the CARMA3 mutant was expressed, the Ang II response was dramatically and specifically impaired (Fig. 2 A) . TNF␣ was used as a control because the NF-B signaling pathway used by the TNF receptor is well characterized and does not require the CARMA, Bcl10, or MALT1 proteins (15) .
To further test the requirement for CARMA3, we constructed an expression vector encoding a short hairpin RNA (shRNA) designed to target human CARMA3 for degradation by the RNAi pathway (Fig. 2B) . When transfected into HepG2 cells, this vector directed efficient, dose-dependent blockade of CARMA3 protein expression (Fig. 2C) . The effect was also specific in that expression of an unrelated protein (IKK␥) was unaffected by CARMA3 shRNA, whereas a control shRNA had no effect on either protein (Fig. 2C) . In functional studies, the CARMA3 shRNA almost completely abolished Ang II- dependent NF-B activation, whereas it had no effect on the TNF␣ response (Fig. 2D) . Importantly, the Ang II response was fully rescued when cells also were transfected with an expression vector encoding mouse CARMA3, whose mRNA sequence contains enough differences from the human sequence to make it an ineffective target for the human CARMA3 shRNA (Fig.  2E) . This ''add-back'' experiment confirms the essential role of CARMA3 in mediating Ang II-dependent NF-B activation. Having established the importance of CARMA3 in Ang II-dependent NF-B activation, we next tested the requirement for Bcl10. Previously, we constructed a Bcl10 mutant that lacks a 13-aa domain near the middle of the protein (25) . This mutant, Bcl10⌬107-119 (Fig.  3A) , is unable to bind the downstream signaling protein, MALT1 and, thus, displays impaired ability to activate NF-B (25) . We reasoned that because this mutant is unable to effectively transmit a signal to MALT1, it might act in a dominant-negative fashion to block Ang II-dependent NF-B activation. Despite its inability to bind MALT1, however, the mutant does enhance background NF-B activity when expressed in transfected cells (Fig. 3A) . The reason for this residual activity is not clear, but we speculate that it may relate to some MALT1-independent effect on NF-B signaling. Nevertheless, when expressed in HepG2 cells, the mutant dramatically impaired the ability of Ang II to induce NF-B beyond background levels (Fig. 3A) . In contrast, TNF␣-mediated induction of NF-B was not affected. These results suggest that Ang II-dependent NF-B activation requires downstream communication between Bcl10 and MALT1.
To confirm the essential role of Bcl10 in Ang II signaling, we compared NF-B activation in primary hepatocytes from WT C57BL͞6 mice and Bcl10 Ϫ/Ϫ mice that had been backcrossed onto the C57BL͞6 genetic background for Ͼ10 generations. In WT cells, Ang II and TNF␣ both induced NF-B (Fig. 3B) . In contrast, Bcl10
Ϫ/Ϫ cells were completely unresponsive to Ang II while simultaneously maintaining their response to TNF␣ (Fig.  3B) . To test whether the lack of Ang II-dependent NF-B activation in Bcl10 Ϫ/Ϫ hepatocytes correlates with impaired cytokine production, we injected WT and Bcl10 Ϫ/Ϫ mice with Ang II and measured liver IL-6 mRNA levels 1 h later. Ang II caused a 4.7-fold induction of IL-6 (compared with PBS vehicle) in WT mice, but the induction in Bcl10 Ϫ/Ϫ mice was significantly reduced at 1.9-fold (Fig. 3C) .
Ang II Induces IKK␥ Ubiquitination: A Role for MALT1. Many distinct receptor-dependent NF-B signaling pathways culminate in the activation of the IKK complex, but the precise mechanisms by which this complex is activated are varied and still poorly understood (15) . However, recent studies have demonstrated that in antigen-stimulated lymphocytes, MALT1 acts through a somewhat unique mechanism by inducing K63-linked ubiquitination of the regulatory subunit, IKK␥ (26, 28 ). Thus, we tested whether Ang II stimulation of HepG2 cells would similarly induce ubiquitination of IKK␥. Cells were transfected with expression vectors encoding myc-tagged IKK␥ and HA-tagged ubiquitin and then treated with either Ang II or TNF␣ as a control. After purification by anti-myc immunoprecipitation, the IKK␥ protein was assayed for ubiquitination by Western blotting with anti-HA (Fig. 4A) . Results showed an increase in polyubiquitinated IKK␥ products, after AII treatment, that were not seen with TNF␣. Simultaneously, Western blotting with anti-myc confirmed equal levels of total IKK␥ purified for each condition.
Importantly, coexpression of the CARMA3 dominant-negative mutant, CARMA3⌬CARD, was effective at blocking Ang IIdependent IKK␥ ubiquitination, suggesting that the ubiquitination event occurs through the same CARMA3-dependent signaling pathway as NF-B activation (Fig. 4B) . To confirm that endogenous IKK␥ also is ubiquitinated after Ang II treatment, we likewise immunoprecipitated endogenous IKK␥ from cells transfected with only HA-tagged ubiquitin and found a similar induction of polyubiquitinated products (Fig. 4C) . Finally, we directly tested the involvement of MALT1 in the Ang IIdependent activation of NF-B by transiently transfecting HepG2 cells with MALT1-specific RNAi duplexes. Western blotting confirmed that the RNAi was effective at reducing MALT1 protein levels by up to 70%, whereas a scrambled RNAi duplex had little effect (Fig. 4D) . In functional analyses, the MALT1 RNAi reduced Ang II-dependent NF-B activation by Ϸ50%, whereas it had no impact on NF-B activation by TNF␣ (Fig. 4D) . Taken together, these results are consistent with a role for MALT1 in Ang II-dependent activation of the IKK complex.
Discussion
The studies described here uncover a discrete signaling pathway used by Ang II for the activation of NF-B in hepatocytes. Although it has been known for some time that Ang II exerts powerful proinflammatory effects in a variety of tissues, little is known regarding the precise molecular mechanisms responsible for these effects. Specifically, although numerous studies have demonstrated that AT 1 R-dependent activation of PKC is crucial for subsequent NF-B activation (30, (34) (35) (36) (37) , until now the intermediate steps linking activated PKC to the IKK complex have remained unclear. Our work demonstrates that a complex of proteins, including CARMA3, Bcl10, and MALT1, appears responsible for transmitting the signal from the AT 1 R to the IKK complex. 
